A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.
Biopharmaceutical company Idenix has cited the “profound consequences for genus claims” in attacking a federal court ruling that affirmed a decision made in a patent dispute with Gilead Sciences.
Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.
A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.
Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.
In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.
Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.
A San Diego biotechnology company has been refused a trademark registration for ‘Sequencing by Binding’ on the grounds that it is too descriptive.
A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.